Treatment of dysfunctional uterine bleeding in the perimenopause: The effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment – a randomized, placebo-controlled, double-blind trial

Autor:	H.R. Franke, F Froukje Snaaijer, Marius J. van der Mooren, Paul W H Houben
Rok vydání:	2006
Předmět:	Abdominal pain medicine.medical_specialty Metrorrhagia Antineoplastic Agents Hormonal Hormone Replacement Therapy Visual analogue scale Endocrinology Diabetes and Metabolism Dysfunctional uterine bleeding Urology Placebo law.invention Endocrinology Double-Blind Method Randomized controlled trial Bone Density law medicine Hormone replacement therapy (male-to-female) Humans Climacteric Gynecology Estradiol business.industry Goserelin Acetate Obstetrics and Gynecology Middle Aged Norethisterone acetate Perimenopause Drug Combinations Goserelin Female Norethindrone medicine.symptom business Mammography medicine.drug
Zdroj:	Gynecological Endocrinology. 22:692-697
ISSN:	1473-0766 0951-3590
Popis:	To assess the effects of adding combined estradiol/norethisterone acetate therapy (CENT) to goserelin acetate treatment (GA) of dysfunctional uterine bleeding (DUB) in perimenopausal women.In a randomized, placebo-controlled, double-blind trial followed by an open follow-up study, 31 perimenopausal women with DUB were recruited from gynecological outpatient departments of two Dutch hospitals and randomized for treatment with either GA/placebo or GA/CENT for 6 months followed by 18 months of GA/CENT for all. The main outcome measures were abdominal pain, number of bleeding days, double-layer endometrial thickness (DET), Greene climacteric score (GCS), visual analog scale for well-being, bone mineral density (BMD) and mammographic density (BI-RAD score).Abdominal pain, number of bleeding days and DET decreased in both groups, the between-group difference in decrease not being statistically significant. GCS initially showed significant improvement in the GA/CENT group. BMD decreased significantly in the GA/placebo group (-4.1%) compared with the GA/CENT group (-0.3%). Another 18 months of GA/CENT did not result in a lasting difference in BMD between groups. BI-RAD scores did not differ significantly between or within the two groups.Adding CENT to GA treatment for DUB in perimenopausal women initially prevented BMD loss and improved climacteric complaints, while having no negative impact on vaginal bleeding, abdominal pain or BI-RAD scores. However, prolonged treatment did not result in a lasting prevention of bone loss.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ef44eb655f951941ba45f2f4e0a9854 https://doi.org/10.1080/09513590601015101 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.